Review
Current Trends in Lipid-Lowering Target Therapy
· 0 citations
· 45 references
Similar papers
Review
Open access
Aug 2026
Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets
This expert position paper proposes practical algorithms for a precision medicine approach in Latin America, matching treatment intensity to individual risk profiles for the primary and secondary prevention of atherosclerotic cardiovascular disease.
C. Ponte-Negretti, A. Lorenzatti, Fernando S. Wyss-Quintana et al.
· Frontiers in Medicine · 0 citations
Review
Open access
Aug 2026
Targeting Dyslipidemia in Ischemic Stroke: Pathophysiology, Clinical Evidence, and Future Perspectives.
An overview of domestic and international guidelines for dyslipidemia is provided and the association between dyslipidemia and ischemic stroke is summarized from the perspectives of pathophysiology, pathological findings, and imaging and blood biomarker.
Junya Aoki
· Journal of atherosclerosis a... · 0 citations
Review
Open access
Jul 2026
NOVEL DIRECTIONS IN LIPID-LOWERING THERAPY FOR THE PREVENTION OF CARDIOVASCULAR DISEASES
Current evidence regarding novel lipid-lowering therapies, their mechanisms of action, clinical efficacy, safety profiles, and future perspectives in the prevention of cardiovascular diseases are summarized.
Galymzhan Qorazov, Ulykbek Daurenov, Aisulu Amirbai et al.
· International Scientific Uni... · 0 citations
Beyond the Pill – The Future of LipidLowering Therapy: A 2026 Review of Novel Lipid-Lowering Agents
These agents have expanded treatment options for patients with familial dyslipidaemia, severe hypertriglyceridaemia, and persistent residual cardiovascular risk while paving the way for precision medicine.
Aryan Arora
· Beyond the Pill – The Future... · 0 citations
Open access
Aug 2026
Intensified lipid-lowering strategies and their effect on atherogenic and metabolic markers in coronary artery disease: a prospective cohort study.
Triple LLT was associated with more comprehensive control of atherogenic lipid markers, with a similar trend for IR markers, and stratified intensification of LLT may support individualized risk-factor management in CAD, although cardiovascular outcome benefits require further validation.
Lei Bao, Zhi-Fan Li, Xiao-Ning Liu et al.
· NMCD. Nutrition Metabolism a... · 0 citations
Open access
Aug 2026
Lipid Profiles and Lipid-Lowering Therapy at the Time of Acute Myocardial Infarction
In a contemporary AMI cohort, combined LLT remained low at presentation and discharge despite suboptimal LDL-C, underscoring actionable gaps in ASCVD management.
Mohammed Essa, Qifan Wu, Yuan Lu et al.
· JACC: Advances · 1 citation